32 results about "Preterm Births" patented technology

The present invention relates to clinical diagnostics including diagnosis, prognosis, prediction, risk assessment and / or risk stratification of preterm birth (PTB) and subsequent treatment in a pregnant subject, and corresponding methods and products. The invention provides decision tools to help clinicians choosing the most appropriate management for the pregnant women. In particular, the present invention relates to a method for the diagnosis, prognosis, prediction, risk assessment and / or risk stratification of preterm birth (PTB) in a pregnant subject, the method comprising determining a level of one or more biomarkers in a sample that has been isolated from said pregnant subject, wherein the one or more biomarkers comprise at least one of matrix metallopeptidase 9 (MMP9) or fragment(s) thereof and Pappalysin-2 (PAPP-A2) or fragment(s) thereof, wherein the level of the one or more biomarkers in the sample is indicative of the presence or absence of a subsequent PTB.

There is provided a computer system and a computer-implemented method for prediction of parameters indicative of the risk of spontaneous preterm birth (sPTB) for a subject under assessment, the method being executed by at least one hardware processor and comprising the steps of: providing one or more ultrasound images comprising medical image data representative of the anatomical structure and appearance of at least a part of a cervix of the subject; providing a plurality of segmentations of the medical image data each representative of one or more features of the anatomical structure and appearance of the at least a part of the cervix of the subject; and utilizing i) the medical image data, ii) spatial information associated with the medical image data and iii) one or more of the segmentations in a classifier model to determine a prediction metric indicative of the likelihood of sPTB for the subject.

The invention discloses a uterine contraction detection method based on multi-modal signal fusion reconstruction, which comprises the following steps of: 1, synchronously acquiring an abdominal surface uterine electromyographic signal in real time through a high-density electrode array, acquiring a uterine contraction pressure signal in cooperation with a fundus pressure sensor, synchronizing a triaxial accelerometer signal to acquire a maternal motion signal, and preprocessing; 2, performing time sequence alignment and resampling on the data, and constructing a quality mask to form a multi-mode uterine contraction signal data set; 3, constructing a reconstruction network based on multi-modal feature fusion; 4, constructing a total loss function of the multi-modal feature fusion reconstruction network; and 5, training a reconstruction network of multi-modal feature fusion, wherein the reconstruction network is used for fusion reconstruction of the multi-modal uterine contraction data. According to the invention, through multi-modal signal fusion and deep feature correlation analysis, accurate monitoring and prediction of uterine contraction and premature delivery risks in the pregnant and birth period can be realized.

The application discloses application of TCTP protein in preparation of noninvasive premature birth diagnosis products and relates to the technical field of biological medicine. The application can estimate the premature birth risk by detecting the TCTP protein content or the TCTP gene expression quantity in peripheral blood of a pregnant woman, the method only needs 0.5ml peripheral blood of the mother, is safe for the mother and infant, and has the advantages of simplicity, high sensitivity, low cost and simple operation. In 126 sample examples in the embodiment of the application, the premature birth detection rate of the method is 91%, and in the control group, the false positive rate is 8.6% (5 examples / 58 examples), so the method has high accuracy.

The invention discloses a premature delivery risk assessment method based on abundance of estradiol degradation genes in excrement samples in the early pregnancy stage, and the method is used for assessing the premature delivery risk of a maternal body based on abundance information of novel estradiol degradation genes in the excrement samples of individuals in the early pregnancy stage. The specific gene is k1412944177, and the nucleotide sequence of the specific gene is SEQ. NO. 1. Research finds that the gene can be used as a biomarker for evaluating the premature delivery risk at the early pregnancy stage, and by detecting the relative abundance of the gene in a maternal excrement sample at the early pregnancy stage, a scientific and accurate risk evaluation basis can be provided for the maternal premature delivery risk. And the expression of the biomarker also has the capability of degrading and regulating estradiol related to premature delivery, so that a brand new thought is provided for precise prevention of premature delivery and individualized obstetrical management.

The disclosure provides biomarker panels, methods and kits for determining the probability for preterm birth in a pregnant female. The present disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing in the future or presently suffering from preterm birth relative to matched controls. The present disclosure is further based, in part, on the unexpected discovery that panels combining one or more of these proteins and peptides can be utilized in methods of determining the probability for preterm birth in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides disclosed herein serve as biomarkers for classifying test samples, predicting a probability of preterm birth, monitoring of progress of preterm birth in a pregnant female, either individually or in a panel of biomarkers.

This invention relates to a group of genes associated with preterm birth, methods for predicting preterm birth in early pregnancy using these genes, and their related applications. Specifically, this invention obtains transcript start site features from at least one of the following genes from the pregnant woman's cfDNA sample: TEX2, WNK1, LINC00970, LOC124900437, IGFL4, LOC105376571, LOC105376577, SERPINB10, LOC642554, and SLC26A7. These transcript start site features are then input into a prediction model, and the output results are used to determine the risk of preterm birth. The prediction model obtained by this invention has higher accuracy than existing models, providing more accurate clinical intervention guidance and reducing medical costs.

A polynucleotide, a kit, an isothermal detection method and a method for predicting premature birth, the method for predicting premature birth comprising: analyzing the expression profile of any one or at least two gene sets in a maternal sample, and predicting whether the subject will have premature birth according to the expression profile. The present application detects the expression amount of the marker gene in the serum of pregnant women for the first time, which is used for the prediction of premature birth risk of pregnant women without clinical symptoms. The main advantage is serological detection, no need to make an appointment in advance like ultrasound, non-invasive detection, no need for vaginal or cervical sampling, and good detection process experience.

This invention provides a kit and detection method for detecting the Siglec fusion mutation gene and the GBS pathogenic gene. It is used for rapid combined detection of the Siglec5 / 14 fusion mutation gene, a preterm birth susceptibility gene, and the GBS pathogenic gene. It can effectively assess the risk of gynecological reproductive tract infections, preterm birth in pregnant women, and infection in newborns. It solves the problem that existing kits only detect the conditionally pathogenic bacteria and have poor specificity for disease association. The detection using this kit is faster and more sensitive. The detection process is closed-loop, avoiding the additional operation of electrophoresis differentiation. It is low-cost and easy to promote.

A system and method for determining cervical stiffness in a patient, to help identify the risk of preterm birth in pregnant patients, based on abnormal changes in cervical stiffness during pregnancy. A probe is inserted to engage the patient's cervix and activated to deform the cervix a predetermined amount. The amount of force needed for the probe to deform the cervix the predetermined amount is measured and a cervical stiffness value can be displayed, based on how much force was needed to deform the cervix the predetermined amount. The probe can include a piston, cuff or loop or an expanding head to deform the cervix. The probe can include the related electronics to activate the probe and display the results as well as preterm birth risk warnings.

The application provides a method and application for inhibiting premature birth of sows or shortening delivery process, and particularly discloses a method and application for inhibiting premature birth of sows or shortening delivery process of sows by using vitamin B6 or derivatives thereof. The application aims at the perinatal period problem of low survival rate of newborn piglets caused by premature birth or long delivery process of sows, and vitamin B6 or derivatives thereof is applied to sows in the late gestation period, and the result shows that the vitamin B6 or derivatives thereof can effectively inhibit premature birth of sows, shorten delivery process of sows and improve the survival rate of piglets, and is an effective method for improving delivery of sows and improving survival of piglets, and provides great value for promoting batch production of sows and high-efficiency breeding, and has important significance for solving the perinatal period premature birth problem in the field of reproduction.

A composition for topical application to the oral cavity, for the use in pregnant women to reduce the risk of preterm birth, comprising an ester of vitamin E with a carboxylic acid of formula R—COOH, in which R is an alkyl radical having 1 to 19 carbon atoms, or an alkenyl or alkynyl radical having 2 to 19 carbon atoms, and an oily vehicle; the ester of vitamin E can be selected from vitamin E acetate, n-propionate or linoleate, preferably alpha-tocopheryl acetate.

A system, device, and method of controlling, supporting, and / or elongating the cervix uteri are provided to treat gestation complications and / or delay the onset of childbirth such that the gestation period of a fetus can be extended to prevent preterm birth and childbirth of the fetus. A cervical control system may include a body configured to be placed in the vagina. The body has an internal channel configured for receiving a cervix therein and an inflatable and / or inflatable inner cuff extending from a portion of the internal channel. The inner cuff may inflate inwardly toward the cervix, or downwardly away from the cervix, or both inwardly and downwardly, such that the inner cuff may engage or clamp the cervix to secure the cervix control system in place while pressing the cervix to close, elongate, and / or adjust the cervix orientation angle.

The invention provides a spontaneous premature delivery prediction system based on machine learning, and belongs to the technical field of gynecological medical data processing and machine learning, and the system comprises a data preprocessing module which is used for obtaining pregnant woman pregnancy and delivery related data from a hospital electronic medical record system and an obstetrical standard data set, and generating an initial independent variable matrix; the model building and training module is used for training the initial independent variable matrix by adopting a Light GBM algorithm and a Transform deep learning model to obtain an initial prediction model; the model optimization module is used for evaluating the contribution degree of each variable to a prediction result by adopting a replacement importance method, screening core independent variables and retraining the model to obtain a simplified prediction model; and the prediction output module is used for preprocessing the clinical data of the to-be-predicted pregnant woman according to the data preprocessing module, inputting the preprocessed clinical data into the simplified prediction model, and outputting spontaneous premature delivery risk probabilities of the corresponding pregnant woman in different pregnancy periods. The technical problem of premature delivery prediction can be practically solved.

The present invention relates generally to the field of compositions comprising myo-inositol for use in the prevention of preterm birth and / or of conditions linked to preterm delivery in a female subject and / or in the offspring. The composition may be a nutritional composition, for example a maternal nutrition composition. The composition may be specifically designed to provide optimized nutrition to a woman desiring to get pregnant or to a pregnant woman.

The application provides a preterm birth prediction method and device based on uterine vector electromyographic signals and a processing device. A novel electrode arrangement scheme is specially designed. The collected uterine vector electromyographic signals are different from traditional uterine surface electromyographic signals, can more comprehensively reflect the spatial characteristics of uterine contraction activities, contain more signal characteristics related to preterm birth, and thus can obtain higher prediction accuracy for preterm birth under the condition of fewer measurement electrodes, and has clinical application value.

Provided are a novel biomarker for predicting preterm birth and an analysis method therefor. This biomarker for predicting preterm birth is at least one selected from the group consisting of oleic acid, myristic acid, lauric acid, margaric acid, and batyl alcohol in amniotic fluid.

The invention discloses a biomarker and a method for evaluating the premature delivery risk of a maternal body at the early pregnancy stage and application of the biomarker, the biomarker is a combination of four microorganisms in intestinal flora, and the four microorganisms are respectively a clostridium-free clostridium strain, an uncertain algal strain, a mucous eubacterium strain CAG: 257 (Blauria sp. CAG: 257) and an eubacterium strain CAG: 251 (Eubacterium sp. CAG: 251). The invention further discloses a method for evaluating the premature delivery risk of the maternal body at the early pregnancy stage. The flora risk score is determined based on the relative abundance information of the various microorganisms in the individual, and the premature delivery risk of the individual can be evaluated in the early pregnancy stage.

Provided are methods of predicting the likelihood of preterm birth (PTB) or early preterm birth (ePTB) for a subject. The methods comprise performing 16S rRNA gene sequencing on vaginal fluid sample DNA to obtain vaginal microbiome 16S rRNA gene sequencing data, and harmonizing the vaginal microbiome 16S rRNA gene sequencing data. The methods further comprise transforming the harmonized vaginal microbiome 16S rRNA gene sequencing data into vaginal microbiome features, inputting the vaginal microbiome features into a predictive model, and predicting, using the predictive model, the likelihood of PTB or ePTB for the subject from whom the vaginal fluid sample was obtained. Computer readable media and systems that find use in practicing the methods of the present disclosure are also provided.

The present application relates to the field of medical data analysis, and more particularly to a method for dynamically predicting the risk of pre-eclampsia premature birth based on monitoring indicators during pregnancy, which comprises: obtaining an individual measured time series set and a basic time weighted average feature; obtaining a recent transient decompensation momentum factor by performing recent deterioration dynamics analysis on monitoring data near the current evaluation time; obtaining a steady-state fracture and barrier breakdown factor by jointly evaluating the evolution trend and fluctuation potential of the historical monitoring sequence; obtaining a reconstructed fusion feature vector by fusing and reconstructing the basic time weighted average feature and the steady-state fracture and barrier breakdown factor; and obtaining a dynamic prediction result of the risk of premature birth by inputting the reconstructed fusion feature vector into a Cox proportional hazards model for risk prediction, thereby solving the problem that the existing prediction method based on time weighted average and linear feature fusion cannot effectively identify recent decompensation deterioration signals and maternal-fetal state deviation risks.

The invention discloses a protein biomarker for auxiliary diagnosis of PCOS spontaneous premature delivery and application thereof, relates to the technical field of biomedicine, and develops reliable diagnosis and early warning for the spontaneous premature delivery of a PCOS pregnant woman in the middle pregnancy period through a biological means. According to the protein biomarker for auxiliary diagnosis of the PCOS spontaneous premature delivery and the application of the protein biomarker, the protein biomarker is PTMA protein, when the protein biomarker is used for diagnosis of the PCOS spontaneous premature delivery in the middle pregnancy period, the accuracy rate reaches 99.5%, the AUC value reaches 0.995, and the diagnosis result is that clinical intervention strives for a key time window of 4-8 weeks. Therefore, more sufficient time is provided for medical staff to formulate and implement personalized intervention strategies, and potential risks of premature delivery can be avoided earlier.

The present invention relates generally to the field of compositions comprising inositol for use in the prevention of preterm birth and / or conditions associated with preterm birth in female individuals and / or offspring. The composition may be a nutritional composition, such as a maternal nutritional composition. The composition may be specifically designed for providing optimized nutrition to women or pregnant women desiring to be pregnant.

The application provides application of a YTHDC1 inhibitor in preparation of a medicine for preventing and treating premature birth, and the medicine takes YTHDC1 gene as a target for placental trophoblasts. The application is based on the fact that the expression level of human YTHDC1 gene in premature placental tissue is significantly higher than that in full-term placenta, a stable overexpression cell strain is constructed aiming at human YTHDC1 gene, and specific siRNA is designed to specifically increase or reduce YTHDC1 expression in human placental trophoblasts, which can correspondingly promote or inhibit the proliferation, apoptosis, migration and invasion ability of the cells. Meanwhile, by injecting in vivo biological preparations interfering with the expression of YTHDC1 gene in an animal model, the expression of YTHDC1 at the placental site can be reduced, the delivery time is prolonged, and the purpose of delaying the occurrence of premature birth is achieved. The application provides a possibility for the development of a clinical premature birth treatment medicine based on YTHDC1 gene, and has great application value and prospect.

A cervical probe, outfitted with a tactile sensor array and an ultrasound transducer, is designed for simultaneous collection of stress and ultrasound strain data from the same cervical sector. The gathered stress and strain data from multiple cervical sectors are sent to a data processor, which calculates cervical elasticity as a strain-to-stress ratio. Subsequently, an average stress-to-strain ratio is compared to a predetermined cutoff value to predict preterm birth at 24-28 gestational weeks.

The present invention relates to a composition for use in pregnant subjects comprising Lactobacillus crispatus cells, wherein said composition minimises and / or prevents pregnancy complications, such as miscarriage, preterm labour and preterm birth.

Provided is a method of preventing and treating an onset of preterm labor and preterm birth, promoting fetal lung development, and reversing inflammation and reducing stress in the uterine environment by administering a pharmaceutically effective amount of Nestorone® (NES) to a pregnant individual in need thereof.

A system for providing information for diagnosing preterm birth risk includes: two or more transmit electrodes, contacting cervical tissues, for applying a plurality of first signals at different frequencies to the cervical tissues, two or more detect electrodes, contacting the cervical tissues, for detecting a plurality of second signals generated in response to the first signals, the second signals corresponding to the first signals, and a source configured to generate a plurality of signals. The system obtains a plurality of impedances of the cervical tissues based on the first and the second signals and applies data quality requirements for diagnosing the preterm birth risk. The data quality requirements include checking at least one of signal generation, signal reception, impedance calculation, quality of the first signals, quality of the second signals, and the impedances. The system includes a diagnosis engine configured to receive data including impedances that satisfy the data quality requirements, classify the data into different groups, each representing different status, based on correlation between the data, patient's information and the preterm birth risk, and output information for diagnosing the preterm birth risk.

An HPC composition and method of treatment for the prevention of PTB and improved neonatal outcomes. The invention provides for a dosing regimen beginning as early as 14 weeks of fetal gestation and dosing regimens of a duration of as much as 25 weeks. The invention provides a high level of exogeneous progestin to endogenous progesterone when it is most needed. The instant invention consistently achieves active levels of HPC which achieve effectiveness. Exemplary dosing regimens comprise an oral administration of HPC in the range of 1,200 mg to 1600 mg, wherein the HPC is administered via a once a day, twice a day, or three times a day administration.

A cervical cup includes a flexible body having a flange to treat preterm birth, the cervical cup being configured to apply suction pressure to the cervix of a patient by compressing the flexible body and holding the flange against the pelvic floor of a patient being treated for preterm birth, the suction pressure being generated by the release of the compression applied to the flexible body. An example of the disclosed methodology to treat preterm birth includes inserting a cervix into a cervical cup and applying a vacuum thereto so as to secure the cervical cup to the cervix.

A method for shortening the duration of mechanical ventilation in premature infants at risk of developing bronchopulmonary dysplasia (BPD) includes administering an effective amount of recombinant human surfactant protein D (rhSP-D) to the infant. In a further embodiment, a method for shortening the length of hospital stay in premature infants at risk of developing BPD includes administering an effective amount of rhSP-D to the infant. In a specific embodiment, a method for reducing the probability that premature infants at risk of developing BPD will develop one or more secondary complications due to preterm birth includes administering an effective amount of recombinant human surfactant protein D (rhSP-D) to the infant. Pharmaceutical compositions for use in the described methods and uses of the pharmaceutical compositions are also described.